• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Hybrid Trials
    • Biotechs
    • CROs
    • Pharma
    • Phase I
    • Phase II/III
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Navigating the Future of Alzheimer’s Treatment

Navigating the Future of Alzheimer’s Treatment

Simplifying ARIA-E Assessment with SSAE Scales

Luc Bracoud, M.Sc. – Senior Director, Medical and Scientific Affairs at Clario
Joyce Suhy, Ph.D. – EVP, Medical Imaging and Specialty Solutions at Clario

Introduction

Alzheimer’s disease (AD) is a pervasive neurodegenerative condition and the leading cause of dementia. Current research and drug development mainly target cerebral amyloid and tau pathologies as the driving forces behind AD-related neurodegeneration. Anti-Aβ monoclonal antibody therapies have seen recent successes after years of disappointing results. Some clinical efficacy was shown, in spite of associated side effects termed amyloid-related imaging abnormalities (ARIA).

This post provides a summary of a contributing research article co-written by Joyce Suhy, Ph.D., EVP, Medical Imaging and Specialty Solutions and Luc Bracoud, M.Sc., Senior Director, Medical and Scientific Affairs – both employed by Clario and published online at https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12503. The article formally describes and validates the visual scales rating the severity of ARIA-E (edema), which were empirically developed by and applied by Clario to most amyloid-targeting treatments being explored over the past two decades.

Anti-Aβ monoclonal antibodies: A promising approach

The clearance of Aβ plaque has emerged as a promising strategy for slowing AD progression. Anti-Aβ monoclonal antibodies (mAbs) have garnered attention for their potential to reduce Aβ plaques in the brain, showing promising results in delaying cognitive and functional decline. Of these, 3 compounds have made significant strides. Aducanumab (Aduhelm) received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2021 and lecanemab (Leqembi) received traditional approval in 2023.  Approval of donanemab was recently submitted to the FDA, with US traditional approval expected in Q1 2024, according to Eli Lilly’s CEO Dave Ricks.

ARIA: Unveiling a challenge in treatment

However, the development of anti-Aβ mAbs came with its own set of challenges, particularly in the form of ARIA. These were first observed during the successive phases of development of bapineuzumab between 2006 and 2013, and have gained attention since then. As first described in 2012, ARIA includes MRI signal abnormalities suggestive of vasogenic edema and sulcal effusions (ARIA-E) and hemosiderin deposits (ARIA-H). While ARIA is mostly asymptomatic, shows a dose-dependance, higher likelihood with early exposure to treatment, and increased risk in APOE4 carriers, its pathophysiological mechanism remains unclear. Due to associated blood-brain barrier alteration, it nevertheless poses a risk that, if left undetected, could lead to severe clinical consequences.

The need for accurate assessment: SSAE-3 and SSAE-5

ARIA-E tends to resolve spontaneously upon treatment interruption, while ARIA-H may at best stabilize after some time. As a means to mitigate adverse reactions to treatment while maximizing patient’s exposure and therefore ensuring optimal amyloid plaque clearance, pharmaceutical companies have designed treatment administration plans which take radiological ARIA severity into account in order to allow treatment continuation in milder ARIA-E cases, and temporary treatment suspension in more severe presentations of ARIA-E, while termination of treatment remains restricted to situations where ARIA-H development becomes a safety concern.

The article introduces the Severity Scales of ARIA-E (SSAE-3 and SSAE-5), simplified rating scales designed both for clinical trial conduct and for practical use in clinical practice. These scales provide a clear and consistent method to assess ARIA-E severity radiologically, facilitating routine MRI monitoring and accurate scoring of ARIA-E in patients undergoing anti-Aβ mAb treatment.

Validation of SSAE-3 and SSAE-5

The article describes how images should be rated, delves into the validation results of the SSAE-3 and SSAE-5 scales, demonstrating high inter- and intra-reader agreements among experienced radiologists, and provides some guidelines for administration. These rating scales offer a practical, understandable, and reliable assessment of ARIA-E severity.

Implications for future Alzheimer’s treatment

As more anti-Aβ mAbs become available, the adoption of standardized MRI protocols and reliable ARIA-E severity assessment tools becomes crucial. The SSAE-3 and SSAE-5 rating scales, with their simplicity and validity, offer a readily available solution for routine clinical practice.  The utilization of our (Clario’s) SSAE-3 scale in the commercial sector is now printed on the FDA labels of both Aduhelm and Leqembi. The article concludes by emphasizing the potential of these scales to support the expansion of anti-Aβ mAbs as a viable treatment option for individuals living with Alzheimer’s disease.

To learn more about this, the article can be found here. Additional insights into scale comparability and treatment management thresholds are presented here.

Read our case study to learn more about Clario’s participation in, and support of, groundbreaking Alzheimer’s disease treatment.

Read case study

Written by

Luc Bracoud headshot

Luc Bracoud, M.Sc.

Senior Director, Medical and Scientific Affairs at Clario

Joyce Suhy headshot

Joyce Suhy, Ph.D.

EVP, Medical Imaging and Specialty Solutions at Clario

Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum